Key Highlights
- Eli Lilly commits $3 billion to Chinese operations spanning the next ten years
- Funding will bolster orforglipron production infrastructure, its oral GLP-1 obesity medication
- Company submitted orforglipron marketing authorization to Chinese regulators in late 2025
- Bernstein maintains Outperform stance with $1,300 price objective; shares currently near $1,008
- LillyConnect platform debut enables employers to tailor GLP-1 benefit packages, working with GoodRx and Cost Plus Drugs
Eli Lilly ($LLY) revealed Wednesday a substantial $3 billion commitment to its Chinese operations over the coming decade. This strategic expansion centers on establishing production facilities for orforglipron, the pharmaceutical giant’s once-daily oral medication addressing type-2 diabetes and weight management.
The pharmaceutical company shared details via WeChat, disclosing that it had previously filed a marketing authorization request for orforglipron with Chinese regulatory authorities at the close of 2025. The submission remains under regulatory evaluation.
Orforglipron represents a non-peptide GLP-1 receptor agonist — distinguishing it from Lilly’s current injectable offerings such as Zepbound. Clinical trial data demonstrated that overweight participants without diabetes achieved an average 12.4% body weight reduction over 72 weeks when administered the maximum dosage.
Additional research indicated that orforglipron successfully maintained weight reduction in patients transitioning from Zepbound or Novo Nordisk’s Wegovy. This finding supports Lilly’s strategy to expand the oral GLP-1 therapeutic category.
Within the China expansion framework, Lilly outlined plans to establish domestic manufacturing capabilities and supply infrastructure for oral solid dose medications. This approach would minimize import dependencies and optimize regional distribution networks.
The strategic announcement positions Lilly alongside other international healthcare corporations expanding Chinese operations, including Haleon and AstraZeneca, which unveiled comparable initiatives earlier this year.
The announcement’s timing carries significance — occurring before an anticipated diplomatic meeting between U.S. President Donald Trump and Chinese President Xi Jinping scheduled for this month.
Not all pharmaceutical leaders are pursuing similar strategies. Bristol-Myers Squibb disclosed in September plans to divest its 60% ownership in a Chinese pharmaceutical partnership, including a Shanghai production facility.
Bernstein Maintains $1,300 Price Objective
Bernstein SocGen reaffirmed its Outperform assessment and $1,300 valuation target on LLY stock recently, following developments regarding GLP-1 distribution channels domestically. Shares are presently trading near $1,008.
The investment firm emphasized CMS guidance on the BALANCE initiative, establishing a $245 Medicaid price threshold for obesity medications beginning May 2026, with Medicare inclusion commencing July 2026. The comprehensive program extends from January 2027 through 2031 — reaching beyond the current administration’s tenure.
Bernstein indicated the extended timeframe delivers pricing stability for Lilly through semaglutide’s patent expiration in 2031.
LillyConnect Platform and Prescription Trends
Recently, Lilly introduced LillyConnect, an innovative platform enabling employers to establish dedicated GLP-1 insurance benefits for workforce members. The company has aligned with 15 program administrators, featuring GoodRx and Mark Cuban’s Cost Plus Drugs, alongside two pharmacy partners: CentreWell and HealthDyne.
The system permits employers to personalize coverage parameters and distribute expenses, potentially reducing copayment amounts versus direct cash payment alternatives.
Morgan Stanley, maintaining an Overweight recommendation with a $1,313 objective, characterized the platform introduction as encouraging. Deutsche Bank similarly holds a Buy rating with a $1,285 target price.
Regarding prescription metrics, Mounjaro recorded approximately 724,500 total prescriptions during the week concluding February 27, representing growth from the previous period. Deutsche Bank identified a 7% sequential weekly recovery in overall GLP-1 prescription volumes.
Morgan Stanley observed that supply limitations had impacted Mounjaro distribution in Brazil, though noted a substantial February import surge suggesting enhanced product availability.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
